Amarin Corporation PLC Q2 2026 Financial Report: Key Highlights and Investor Insights
Overview
Amarin Corporation PLC (Nasdaq: AMRN), a pharmaceutical company specializing in cardiovascular health, has released its Form 10-Q for the second quarter ended June 30, 2026. The report contains detailed financial statements, operational updates, and disclosures relevant to shareholders and potential investors.
Key Points from the Report
- Financial Position: Amarin reported total assets of \$624.4 million as of June 30, 2026, compared to \$670.8 million as of December 31, 2025. This represents a reduction of approximately \$46.4 million over six months, primarily attributed to a decrease in cash and short-term investments.
-
Cash and Short-Term Investments:
- Cash and cash equivalents: Not specifically stated, but restricted cash reported at \$201,000.
- Short-term investments: \$171.1 million as of June 30, 2026, down from \$167.9 million at year-end 2025.
- Current assets total: \$602.8 million (Q2 2026), down from \$649.9 million (FY 2025).
- Prepaid Expenses and Other Current Assets: \$24.4 million as of June 30, 2026, compared to previous periods.
- Intangible Assets: Finite-lived intangible assets net were \$12.1 million as of June 30, 2026, slightly down from \$12.1 million at year-end.
-
Stockholders’ Equity:
- Ordinary shares outstanding: 420,044,002 as of June 30, 2026; 416,214,102 as of December 31, 2025.
- Common stock value: \$310.2 million as of June 30, 2026.
- Additional paid-in capital: \$1.92 billion.
- Current Liabilities: Specific breakdown not provided, but other current liabilities are \$11.3 million as of June 30, 2026 (vs. \$10.9 million at year-end).
- Commitments and Contingencies: The report notes commitments and contingencies, but values are not disclosed (see Note 5).
- Trading Symbol and Exchange: AMRN on Nasdaq Stock Market LLC.
Shareholder Information and Potential Price Sensitive Items
-
Share Count Changes:
- Ordinary shares outstanding increased by 3.83 million shares in six months, a potential dilution (from 416,214,102 to 420,044,002).
- Investors should monitor the impact of increased shares on earnings per share and overall dilution.
-
Decrease in Assets:
- The reduction of total assets, particularly cash and investments, may indicate increased spending, investment, or operational challenges, which could impact future liquidity and financial flexibility.
-
Commitments and Contingencies:
- The 10-Q references unspecified commitments and contingencies (Note 5). If material, these could impact Amarin’s financial position or share price. Shareholders should look for further disclosures in Note 5.
-
Regulatory and Market Status:
- Amarin is not a shell company, nor an emerging growth company. It is classified as a non-accelerated filer and not a smaller reporting company, indicating its maturity and reporting obligations.
-
Nasdaq Compliance:
- Amarin has filed all required reports and submitted all interactive data files as required by SEC regulations, maintaining compliance with Nasdaq listing standards.
-
International Operations:
- Business address and operations remain in Dublin, Ireland, reflecting Amarin’s global profile.
-
Potential Newsworthy Items:
- The increase in share count, decrease in assets, and reference to undisclosed commitments and contingencies are all potentially price-sensitive.
- Any material changes in commitments or contingencies disclosed in Note 5, or significant operational updates in the Management’s Discussion and Analysis section, could impact the share price.
Investor Considerations
Investors should closely monitor Amarin’s liquidity and asset trends, especially regarding cash and investments. The increase in share count warrants attention for dilution risk. The reference to commitments and contingencies, without specific values, is a red flag for potential undisclosed liabilities or ongoing legal/regulatory matters. Amarin’s continued compliance with Nasdaq and SEC requirements is positive, but any future changes in financial or operational status should be watched closely.
Conclusion
The Q2 2026 report from Amarin Corporation PLC reveals several important financial and operational details. While there are no major surprises, the decrease in assets and increase in share count, combined with undisclosed commitments and contingencies, are factors that could materially affect shareholder value and share price. Investors should review upcoming disclosures and monitor Amarin’s financial health and operational strategy.
Disclaimer: This article is based on Amarin Corporation PLC’s Q2 2026 SEC Form 10-Q public filings. It is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information herein is subject to change and may not reflect the most current company updates.
